Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07155239 · ClinicalTrials.gov registry record · Phase 1

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

A Phase 1 study of Hidradenitis Suppurativa (HS), sponsored by Wynn Medical Center.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT07155239 is a Phase 1 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Wynn Medical Center. The registered enrollment target is 30 participants, below the 178-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07155239, a Phase 1 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Wynn Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin. HS begins around the hair follicle; when the follicle becomes blocked and inflamed, new lesions form. Prior clinical studies of lasers that act on the hair follicle have shown improvement in HS symptoms, and a 1726-nm diode laser-designed to selectively heat oil glands within the follicle-has reduced inflammatory lesions in acne with good tolerability across many skin types. This study will test whether a 1726-nm diode laser can safely reduce inflammatory HS lesions in Hurley stage I-II disease. Adults with bilateral (right/left) affected areas will be randomized so that one side receives active laser treatment and the other side receives a sham procedure. Participants will have three treatment sessions over 8 weeks and follow-up through Week 24 while continuing their stable HS medications. The primary outcome is the percent change in abscess and inflammatory nodule counts on the treated side versus the sham side at Week 16. Secondary outcomes include validated HS responder scores, pain, quality of life, flare rate/antibiotic use, and safety. Results may support a non-ablative, follicle-directed option for early HS.

Conditions Studied

Hidradenitis Suppurativa (HS)

Interventions

  • DEVICE Sham (No Treatment)
  • DEVICE AviClear Lase Treatment

Study Locations (1)

California

  • Wynn Medical Center Rheumatology/Dermatology - Rosemead

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-09-15
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Wynn Medical Center

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07155239

The ClinicalTrials.gov registry entry for NCT07155239 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (83% lower). The listed sponsor is Wynn Medical Center, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 2 interventions - of which Sham (No Treatment) is the first listed.

NCT07155239 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07155239 about?

NCT07155239 is a clinical study titled "1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)". Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin. HS begins around the hair follicle; when the follicle becomes blocked and inflamed, new lesions form. Prior clinical studies of lasers that act on ...

What is the current status of trial NCT07155239?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-15. Estimated completion is 2026-12-31.

What conditions does trial NCT07155239 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).

What interventions are being tested in trial NCT07155239?

The interventions under investigation include: Sham (No Treatment) (DEVICE), AviClear Lase Treatment (DEVICE).

Who is sponsoring clinical trial NCT07155239?

This trial is sponsored by Wynn Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07155239 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa (HS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hidradenitis Suppurativa (HS)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.